keyword
MENU ▼
Read by QxMD icon Read
search

Modafinil

keyword
https://www.readbyqxmd.com/read/28525569/comparative-effects-of-methylphenidate-modafinil-and-mdma-on-response-inhibition-neural-networks-in-healthy-subjects
#1
André Schmidt, Felix Müller, Patrick C Dolder, Yasmin Schmid, Davide Zanchi, Matthias E Liechti, Stefan Borgwardt
Background: Psychostimulants such as methylphenidate (MPH) and modafinil are increasingly used by healthy people for cognitive enhancement purposes, whereas the acute effect of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on cognitive functioning in healthy subjects remains unclear. This study directly compared the acute effects of MPH, modafinil and MDMA on the neural mechanisms underlying response inhibition in healthy subjects. Methods: Using a double-blind within-subject placebo-controlled cross-over design, MPH, modafinil and MDMA were administrated to 21 healthy subjects, while performing a Go/No-Go event-related functional magnetic resonance imaging task to assess brain activation during motor response inhibition...
May 19, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28499899/the-wake-promoting-drug-modafinil-prevents-motor-impairment-in-sickness-behavior-induced-by-lps-in-mice-role-for-dopaminergic-d1-receptor
#2
Adriano Zager, Wesley Nogueira Brandão, Rafael Oliveira Margatho, Jean Pierre Peron, Sergio Tufik, Monica Levy Andersen, Birgitte Rahbek Kornum, João Palermo-Neto
The wake-promoting drug Modafinil has been used for many years for treatment of Narcolepsy and Excessive Daytime Sleepiness, due to a dopamine-related psychostimulant action. Recent studies have indicated that Modafinil prevents neuroinflammation in animal models. Thus, the aim of the present study was to evaluate the effect of Modafinil pretreatment in the Lipopolysaccharide (LPS)-induced sickness and depressive-like behaviors. Adult male C57BL/6J mice were pretreated with Vehicle or Modafinil (90mg/Kg) and, 30min later, received a single saline or LPS (2mg/Kg) administration, and were submitted to the open field and elevated plus maze test 2h later...
May 9, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28490912/update-on-the-treatment-of-narcolepsy-clinical-efficacy-of-pitolisant
#3
REVIEW
Michael W Calik
Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS). In 60-70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. Narcolepsy decreases the quality of life of the afflicted individuals. Currently used drugs treat EDS alone (modafinil/armodafinil, methylphenidate, and amphetamine), cataplexy alone ("off-label" use of antidepressants), or both EDS and cataplexy (sodium oxybate)...
2017: Nature and Science of Sleep
https://www.readbyqxmd.com/read/28481358/decreased-alertness-due-to-sleep-loss-increases-pain-sensitivity-in-mice
#4
Chloe Alexandre, Alban Latremoliere, Ashley Ferreira, Giulia Miracca, Mihoko Yamamoto, Thomas E Scammell, Clifford J Woolf
Extended daytime and nighttime activities are major contributors to the growing sleep deficiency epidemic, as is the high prevalence of sleep disorders like insomnia. The consequences of chronic insufficient sleep for health remain uncertain. Sleep quality and duration predict presence of pain the next day in healthy subjects, suggesting that sleep disturbances alone may worsen pain, and experimental sleep deprivation in humans supports this claim. We demonstrate that sleep loss, but not sleep fragmentation, in healthy mice increases sensitivity to noxious stimuli (referred to as 'pain') without general sensory hyper-responsiveness...
May 8, 2017: Nature Medicine
https://www.readbyqxmd.com/read/28464963/modafinil-and-cognitive-enhancement-in-schizophrenia-and-healthy-volunteers-the-effects-of-test-battery-in-a-randomised-controlled-trial
#5
J Lees, P G Michalopoulou, S W Lewis, S Preston, C Bamford, T Collier, A Kalpakidou, T Wykes, R Emsley, G Pandina, S Kapur, R J Drake
BACKGROUND: Cognitive deficits in schizophrenia have major functional impacts. Modafinil is a cognitive enhancer whose effect in healthy volunteers is well-described, but whose effects on the cognitive deficits of schizophrenia appear to be inconsistent. Two possible reasons for this are that cognitive test batteries vary in their sensitivity, or that the phase of illness may be important, with patients early in their illness responding better. METHODS: A double-blind, randomised, placebo-controlled single-dose crossover study of modafinil 200 mg examined this with two cognitive batteries [MATRICS Consensus Cognitive Battery (MCCB) and Cambridge Neuropsychological Test Automated Battery (CANTAB)] in 46 participants with under 3 years' duration of DSM-IV schizophrenia, on stable antipsychotic medication...
May 3, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28443381/pharmacological-management-of-narcolepsy-with-and-without-cataplexy
#6
Ulf Kallweit, Claudio L Bassetti
Narcolepsy is an orphan neurological disease and presents with sleep-wake, motoric, neuropsychiatric and metabolic symptoms. Narcolepsy with cataplexy is most commonly caused by an immune-mediated process including genetic and environmental factors, resulting in the selective loss of hypocretin-producing neurons. Narcolepsy has a major impact on workableness and quality of life. Areas covered: This review provides an overview of the temporal available treatment options for narcolepsy (type 1 and 2) in adults, including authorization status by regulatory agencies...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28429997/attitudes-toward-cognitive-enhancer-use-among-new-zealand-tertiary-students
#7
Sanyogita Sanya Ram, Safeera Hussainy, Marcus Henning, Kay Stewart, Maree Jensen, Bruce Russell
BACKGROUND: Cognitive enhancement is the use of prescription stimulant medicines by healthy individuals for nonmedical use in academic settings. Commonly used cognitive enhancers (CEs) include methylphenidate, amphetamines, and modafinil. To understand the motivation to use CEs, it is important to look beyond prevalence and explore the extent to which attitudes, beliefs, and intentions predict the decision to use CEs. OBJECTIVE: The study aimed to investigate what factors explain the decision to use CEs among tertiary students in New Zealand, using the Theory of Planned Behaviour (TPB)...
April 21, 2017: Substance Use & Misuse
https://www.readbyqxmd.com/read/28429147/docetaxel-related-fatigue-in-men-with-metastatic-prostate-cancer-a-descriptive-analysis
#8
A R T Bergin, E Hovey, A Lloyd, G Marx, P Parente, T Rapke, P de Souza
PURPOSE: Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention. METHODS: This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]...
April 20, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28424611/modafinil-induced-changes-in-functional-connectivity-in-the-cortex-and-cerebellum-of-healthy-elderly-subjects
#9
Miriam Punzi, Tommaso Gili, Laura Petrosini, Carlo Caltagirone, Gianfranco Spalletta, Stefano L Sensi
In the past few years, cognitive enhancing drugs (CEDs) have gained growing interest and the focus of investigations aimed at exploring their use to potentiate the cognitive performances of healthy individuals. Most of this exploratory CED-related research has been performed on young adults. However, CEDs may also help to maintain optimal brain functioning or compensate for subtle and or subclinical deficits associated with brain aging or early-stage dementia. In this study, we assessed effects on resting state brain activity in a group of healthy elderly subjects undergoing acute administration of modafinil, a wakefulness-promoting agent...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28424564/new-developments-in-the-management-of-narcolepsy
#10
REVIEW
Vivien C Abad, Christian Guilleminault
Narcolepsy is a life-long, underrecognized sleep disorder that affects 0.02%-0.18% of the US and Western European populations. Genetic predisposition is suspected because of narcolepsy's strong association with HLA DQB1*06-02, and genome-wide association studies have identified polymorphisms in T-cell receptor loci. Narcolepsy pathophysiology is linked to loss of signaling by hypocretin-producing neurons; an autoimmune etiology possibly triggered by some environmental agent may precipitate hypocretin neuronal loss...
2017: Nature and Science of Sleep
https://www.readbyqxmd.com/read/28404841/midas-modafinil-in-debilitating-fatigue-after-stroke-a-randomized-double-blind-placebo-controlled-cross-over-trial
#11
Andrew Bivard, Thomas Lillicrap, Venkatesh Krishnamurthy, Elizabeth Holliday, John Attia, Heather Pagram, Michael Nilsson, Mark Parsons, Christopher R Levi
BACKGROUND AND PURPOSE: This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke. We hypothesized that 200 mg of modafinil daily for 6 weeks would result in reduced symptoms of fatigue compared with placebo. METHODS: This single-center phase 2 trial used a randomized, double-blind, placebo-controlled, crossover design. The key inclusion criterion was a multidimensional fatigue inventory score of ≥60...
May 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28374089/modafinil-enhances-alerting-related-brain-activity-in-attention-networks
#12
Yumiko Ikeda, Takuya Funayama, Amane Tateno, Haruhisa Fukayama, Yoshiro Okubo, Hidenori Suzuki
RATIONALE: Modafinil is a wake-promoting agent and has been reported to be effective in improving attention in patients with attentional disturbance. However, neural substrates underlying the modafinil effects on attention are not fully understood. OBJECTIVES: We employed a functional magnetic resonance imaging (fMRI) study with the attention network test (ANT) task in healthy adults and examined which networks of attention are mainly affected by modafinil and which neural substrates are responsible for the drug effects...
April 3, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28364419/sleep-perception-and-misperception-in-chronic-cocaine-users-during-abstinence
#13
Sarah E Hodges, Brian Pittman, Peter T Morgan
Study Objectives: During abstinence, chronic cocaine users experience an objective worsening of sleep that is perceived as qualitatively improving. This phenomenon has been termed "occult insomnia." The objective of this study was to determine whether chronic cocaine users experience positive sleep state misperception during abstinence. Methods: Forty-three cocaine-dependent persons were admitted to an inpatient research facility for 12 days and 11 nights to participate in a treatment study of modafinil...
March 1, 2017: Sleep
https://www.readbyqxmd.com/read/28350194/modafinil-treatment-of-cocaine-dependence-a-systematic-review-and-meta-analysis
#14
Dinesh Sangroula, Fatima Motiwala, Bivek Wagle, Vivek C Shah, Katsuhiko Hagi, Steven Lippmann
BACKGROUND: Currently, there is none FDA-approved medication to treat cocaine dependency. Studies conducted with various medications, including antipsychotics, antidepressants, anticonvulsants, and others, revealed inconsistent results. OBJECTIVES: To meta-analytically investigate the efficacy and safety of modafinil in the treatment of cocaine-dependent patients. METHODS: Randomized controlled trials with ≥20 subjects comparing the numerical therapeutic outcomes of modafinil with placebo were identified in databases, such as PUBMED, psycINFO, EMBASE, and Clinicaltrials...
March 28, 2017: Substance Use & Misuse
https://www.readbyqxmd.com/read/28318897/efficacy-of-off-label-augmentation-in-unipolar-depression-a-systematic-review-of-the-evidence
#15
REVIEW
Julia Kleeblatt, Felix Betzler, Laura L Kilarski, Tom Bschor, Stephan Köhler
Treatment of unipolar depression with currently available antidepressants is still unsatisfactory. Augmentation with lithium or second generation antipsychotics is an established practice in non-responders to antidepressant monotherapy, but is also associated with a substantial non-response rate and with non-tolerance. Based on a systematic review of the literature, including meta-analyses, randomized controlled trials (RCTs), non-randomized comparative studies and case studies, off-label augmentation agents (administered in addition to an antidepressant, without FDA approval for treatment of MDD) were identified and evaluated regarding their efficacy using levels of evidence...
March 16, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28299368/modafinil-improves-episodic-memory-and-working-memory-cognition-in-patients-with-remitted-depression-a-double-blind-randomized-placebo-controlled-study
#16
Muzaffer Kaser, Julia B Deakin, Albert Michael, Camilo Zapata, Rachna Bansal, Dragana Ryan, Francesca Cormack, James B Rowe, Barbara J Sahakian
BACKGROUND: Cognitive dysfunction is a core feature of depression and tends to persist even after mood symptoms recover, leading to detrimental effects on clinical and functional outcomes. However, most currently available treatments have not typically addressed cognition. Modafinil has been shown to have beneficial effects on cognitive function and therefore has the potential to improve cognition in depression. The objective of this double-blind, placebo-controlled study was to investigate the effects of modafinil on cognitive functions in patients with remitted depression...
March 2017: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/28266501/the-novel-modafinil-analog-jjc8-016-as-a-potential-cocaine-abuse-pharmacotherapeutic
#17
Hai-Ying Zhang, Guo-Hua Bi, Hong-Ju Yang, Yi He, Gilbert Xue, Jiajing Cao, Gianluigi Tanda, Eliot L Gardner, Amy Hauck Newman, Zheng-Xiong Xi
(±)Modafinil ((±)MOD) and its R-enantiomer (R-modafinil; R-MOD) have been investigated for their potential as treatments for psychostimulant addiction. We recently reported a series of (±)MOD analogs, of which JJC8-016 (N-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)-3-phenylpropan-1-amine) was selected for further development. JJC8-016 and R-MOD were evaluated for binding across ~70 receptors, transporters, and enzymes. Although at a concentration of 10 μM, there were many hits for JJC8-016, binding affinities in the range of its DAT affinity were only observed at the serotonin transporter (SERT), dopamine D2-like, and sigma1 receptors...
March 29, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28256707/dopaminergic-agents-in-the-treatment-of-bipolar-depression-a-systematic-review-and-meta-analysis
#18
A G Szmulewicz, F Angriman, C Samamé, A Ferraris, D Vigo, S A Strejilevich
OBJECTIVE: To systematically examine the effects of dopaminergic agents (modafinil, armodafinil, pramipexole, methylphenidate, and amphetamines) on bipolar depression outcomes. METHODS: Meta-analysis of randomized controlled trials was performed to assess the efficacy and safety of treatment with dopaminergic agents in bipolar depression. In a secondary analysis, findings from both randomized controlled trials and high-quality observational studies were pooled by means of meta-analytic procedures to explore dopaminergic treatment-related new mania...
June 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28244162/exploring-the-effect-of-ginsenoside-rh1-in-a-sleep-deprivation-induced-mouse-memory-impairment-model
#19
Cong Lu, Zhe Shi, Liming Dong, Jingwei Lv, Pan Xu, Yinghui Li, Lina Qu, Xinmin Liu
Panax ginseng C.A. Meyer (Araliaceae) has been used in traditional Chinese medicine for enhancing cognition for thousands of years. Ginsenoside Rh1, a constituent of ginseng root, as with other constituents, has memory-improving effects in normal mice and scopolamine-induced amnesic mice. Sleep deprivation (SD) is associated with memory impairment through induction of oxidative stress. The present study investigated the effect of Rh1 against SD-induced cognitive impairment and attempted to define the possible mechanisms involved...
February 28, 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/28231529/new-enantioselective-lc-method-development-and-validation-for-the-assay-of-modafinil
#20
Marianna Harvanová, Taťána Gondová
For the first time, a new, fast and sensitive chromatographic method for the separation and determination of modafinil enantiomers was developed on chiral stationary phase with macrocyclic glycopeptide teicoplanin in the polar organic mode. The effect of the mobile phase composition and column temperature on the retention and enantioseparation were studied. The separation was performed using a Chirobiotic T column (250×4.6mm, 5μm) with methanol and triethylamine (100/0.05, v/v) as the mobile phase at a flow rate of 1...
February 16, 2017: Journal of Pharmaceutical and Biomedical Analysis
keyword
keyword
5558
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"